IngredientsFucus vesiculosus, known by the common names bladderwrack, black tang, rockweed, sea grapes, bladder fucus, sea oak, cut weed, dyers fucus, red fucus, and rock wrack, is a brown alga (a seaweed) found on the coasts of the North Sea, the western Baltic Sea and the Atlantic and Pacific Oceans. The botanical name is derived from the Greek word phykos, meaning "seaweed," and the Latin term vesiculosus, which translates as "with bladder."
The fronds of F. vesiculosus grow to 150 cm long and 2.5 cm wide and have a prominent midrib throughout. It is typically attached by a basal disc-shaped holdfast but can also be unattached. It has almost spherical air bladders, which are usually paired one on either side of the mid-rib but may be absent in young plants. The margin is smooth and the frond is dichotomously branched.
Fucus vesiculosus L., known as bladderwrack, belongs to the brown seaweeds, which are widely distributed throughout northern Russia, Atlantic shores of Europe, the Baltic Sea, Greenland, the Azores, the Canary Islands, and shores of the Pacific Ocean. Bladderwrack is a cold-to-temperate water species found on both North Atlantic coasts, the North Sea, and the western Baltic Sea. Fucus plays an especially important role in the Baltic, where it is the only large brown alga that naturally occurs there and the predominant canopy species.
The plant belongs to the family Fucaceae, order Fucales, class Phaeophyceae (brown algae). The whole plant (thallus) is used as medicine. It was the original source of iodine, discovered in 1811, and was used extensively to treat goitre.
Bladderwrack can be prepared in several forms, including teas, powders, capsules, and extracts, depending on personal preference and intended use. It has a long history of traditional use and is associated with food and botanical traditions, often valued for its savory flavor and sometimes used as a natural salt alternative. Tea preparations typically involve steeping the dried herb for several minutes, while powdered forms can be incorporated into recipes or encapsulated. It continues to be used today as a dried herb or as an aqueous alcohol tincture in a number of health supplements available throughout the world.
The Martindale reference describes a soft extract prepared with ethanol (45%) at a dose of 200 to 600 mg, and a liquid extract prepared with ethanol (45%) at a dose of 4 to 8 ml, though the number of daily intakes is not mentioned.
Bladderwrack has a long history of use dating back at least to the early 1300s, when King Denis of Portugal (known as the Farmer King) regulated the harvest of cast-ashore seaweeds, Fucus being one of them.
In traditional European herbalism, bladderwrack was documented as early as the 17th century for its ability to support thyroid function — especially after it was observed that coastal communities consuming seaweed had fewer cases of goiter, a thyroid-related swelling of the neck. British and Irish herbalists used it for its metabolism-boosting properties, and it was even listed in early editions of the U.S. Pharmacopeia.
Nineteenth-century eclectic physicians documented bladderwrack as a specific remedy for enlarged thyroid and for constitutional presentations they described as "sluggish metabolism." Their clinical observations noted improvements in weight management, energy levels, and cold tolerance in clients who used bladderwrack preparations consistently over several weeks. British herbalists of the same era categorized bladderwrack as a "metabolic stimulant," and noted its traditional use in coastal communities where goiter was rare compared to inland populations.
Bladderwrack's mucilaginous thallus has long been used to soothe irritated and inflamed tissues in the body, and it was also historically used as a bulk-forming laxative. It has also been used to counter obesity, possibly due to its reputation for stimulating the thyroid gland.
Traditional medicinal practices have used it for centuries to treat an array of conditions, such as iodine deficiency, obesity, joint pain, aging skin, digestive issues, urinary tract infection, and thyroid dysfunction, including hyperthyroidism, hypothyroidism, and goiter development.
In Japan, Korea, and China, varieties of brown seaweed (including bladderwrack relatives) were used to support digestion, balance fluids, and nourish the body postpartum.
Traditional preparations included several forms. Dried, cut bladderwrack was simmered in water for 15 to 20 minutes to create a mineral-rich decoction — the most common preparation in 19th-century herbal practice, taken as a daily tonic. Alcohol-extracted tincture preparations were also used in eclectic medicine for more targeted dosing, and the tincture form allowed practitioners to combine bladderwrack with other herbs more precisely.
Beyond medicine, bladderwrack had important non-medicinal uses. During the 19th century, at the time of the Napoleonic wars, seaweeds including bladderwrack were burned for their ash, which is a rich source of potash and soda ash necessary for the production of gunpowder; in more peaceful times, these were used for the manufacture of glass and by the soap industry of the era. Traditionally it was also used as a crop fertilizer in places including Cornwall, Jersey, and the Isles of Scotland, where it would be gathered from the shoreline and spread directly on beds containing stable crops such as potatoes.
There are three major active constituents in bladderwrack: iodine, alginic acid, and fucoidan. Primary chemical constituents also include mucilage, mannitol, fucitol, beta-carotene, zeaxanthin, volatile oils, bromine, and potassium and other minerals.
Bladderwrack contains variable amounts of iodine, up to 600 mg/g. Much of the iodine content is organically bound, a more potent thyroid-stimulating form than mineral-bound iodine. The amount of iodine in bladderwrack is highly variable, probably as a result of different amounts of iodine in the water where it grows. Bladderwrack is used as a natural source of iodine; the iodine content gives some plausibility to a possible stimulating effect on the thyroid gland.
Fucoidan is a major fucose-rich sulfated polysaccharide found in Fucus vesiculosus. Fucoidan is a type of dietary fiber that contains numerous sulfur groups. According to test tube and animal studies, this appears to give fucoidan several properties, such as lowering LDL cholesterol levels, lowering blood glucose levels, anti-inflammatory activity, possible anticoagulant effects, and antibacterial and anti-HIV activity. Fucoidan is thought to prevent bacteria and viruses from binding to human cells — a necessary step in starting an infection — as opposed to killing the microbes directly, though this has not been definitively proven.
Fucoidan, a sulfated glycosaminoglycan derived from F. vesiculosus, has shown stronger antithrombotic activity compared to heparin in vivo and reduced inflammation and proliferation in vascular cells in vitro.
An over-the-counter antacid, Gaviscon®, containing magnesium carbonate and sodium alginate (the sodium salt of alginic acid), has been shown to effectively relieve the symptoms of heartburn compared to other antacids in a double-blind study; however, bladderwrack itself has not been studied for use in people with heartburn. Alginic acid may help lower LDL ("bad") cholesterol levels, according to animal studies, though no human trials have studied this effect of bladderwrack. Of particular interest is the alginic acid polysaccharide content, responsible for gel-forming and water-holding properties of Fucus species, as well as the polyphenol phlorotannins.
Due to their large spectrum of bioactive properties, much attention has recently been drawn to phlorotannins — phenolic compounds characteristic of brown macroalgae. Phlorotannins from Fucus vesiculosus are gaining attention for their diverse biological effects, including antioxidant, anti-diabetic, anti-obesity, anticancer, and anti-inflammatory properties.
Research has provided evidence of antioxidant and anti-inflammatory activities of F. vesiculosus phlorotannin extracts and purified fractions, as reflected by their ability to scavenge chemically generated reactive oxygen species (ROS) and inhibit inflammatory response in LPS-stimulated macrophages. Of the intracellular markers analyzed, inducible nitric oxide synthase showed the highest sensitivity to almost all phlorotannin-rich samples, followed by interleukin 1β and cyclooxygenase 2. Furthermore, one subfraction inhibited the phosphorylation and degradation of inhibitory protein κBα, thus preventing the activation of NF-κB and blocking the inflammatory cascade at the transcriptional level.
Like most seaweeds, bladderwrack consists of fiber, polysaccharides, minerals (calcium, iodine, magnesium, potassium, sodium, zinc), and vitamins A, C, and K. It is also rich in calcium, iodine, magnesium, potassium, sodium, zinc, and vitamins A and C. The EMA assessment report also identifies in bladderwrack the carotenoids lutein, violaxanthin, neoxanthin, fucoxanthinol, β-carotene, and squalene. Fucoxanthin, a carotenoid found on the surface of F. vesiculosus, has been identified as an antimicrobial agent that inhibits bacterial settlement.
Most evidence for bladderwrack is derived from in vitro cell studies and rodent models, with very few randomized controlled trials in humans. The following sections characterize the state of evidence for each therapeutic area, separating in vitro and animal findings clearly from human clinical data.
Bladderwrack was the original source of iodine, discovered in 1811, and was used extensively to treat goitre, a swelling of the thyroid gland related to iodine deficiency. It is used as a natural source of iodine, and the iodine content gives some plausibility to a possible stimulating effect on the thyroid gland.
There are no studies of efficacy, dosing, or safety to support its use for thyroid conditions, and no standardization of iodine content. Using seaweeds with the rationale that the iodine content is what is affecting treatment may be erroneous, as most thyroid insufficiency in the United States is not attributable to iodine deficiency. Furthermore, excess iodine can contribute to or worsen hypothyroidism.
Evidence strength: There is plausible biological reasoning (iodine content), but no human clinical trials specifically testing bladderwrack for hypothyroidism, hyperthyroidism, or goiter. People use Fucus vesiculosus for thyroid disorders and iodine deficiency, but there is no good scientific evidence to support these uses.
The EMA assessment places Fucus in the category of an adjuvant in slimming diets rather than a stand-alone treatment. Clinical research in this area has failed to confirm that seaweeds like bladderwrack help with weight loss, though more specific research is warranted. Early research suggests that taking Fucus vesiculosus along with lecithin and vitamins does not help people lose weight.
The EMA wording is revealing: it means the seaweed may play a supporting role, mainly through bulk, fiber-like effects, and perhaps through correcting low iodine in selected cases, but it is not a proven fat-loss agent.
Evidence strength: Weak. The alginic acid content may contribute to satiety through gel-forming fiber effects, but no adequately powered randomized controlled trials have demonstrated meaningful weight loss attributable to bladderwrack alone.
Bladderwrack is one of the marine algae that has been used historically as an herbal medicine to address a variety of complaints, including sore joints, obesity, and fatigue.
Two human trials have examined fucoidan from F. vesiculosus for joint symptoms. In a pilot study of 12 people with osteoarthritis (OA) of the knee, a fucoidan supplement given for three months reduced symptoms of arthritis by 18% at a dose of 100 mg and by 52% at a dose of 1,000 mg. However, 255 mg fucoidan from bladderwrack was as effective as placebo in another trial of 122 people with OA of the knee and hip.
The larger and more methodologically robust trial reached a null result. The F. vesiculosus fucoidan extract was safe and well tolerated. At a dose of 300 mg, the extract showed no difference in reduction of OA symptoms from placebo. There were no changes in blood measurements that were of any clinical significance during the course of the study.
In a cell-based study, fucoidan reduced the viability, survival, and invasiveness of the cells that trigger rheumatoid arthritis (fibroblast synoviocytes), by reducing the activation of the NF-κB and p38 inflammatory pathways.
Evidence strength: Mixed and currently insufficient. The larger RCT (n=122) found no benefit at 300 mg of F. vesiculosus fucoidan over placebo; the smaller pilot study was positive but underpowered and lacked a placebo arm. Cell-based mechanistic evidence exists but does not translate directly to clinical benefit.
Research on F. vesiculosus phlorotannin extracts has shown good radical scavenging activity, particularly towards nitric oxide. Subsequent subfractions were shown to inhibit lipopolysaccharide-induced nitric oxide production in macrophages, with stronger effects observed for fractions of lower molecular weights. One subfraction inhibited the phosphorylation and degradation of inhibitory protein κBα, thus preventing the activation of NF-κB and blocking the inflammatory cascade at the transcriptional level.
Concerning fucoidan specifically: an exploratory prospective clinical study for advanced cancer patients revealed that levels of important proinflammatory cytokines, including IL-1β, IL-6, and TNF-α, were significantly reduced after a short period of fucoidan administration. A subgroup analysis showed that the responsiveness of IL-1β was significantly correlated with overall survival, suggesting it might be a useful prognostic biomarker for advanced cancer patients receiving fucoidan. This was described as the first study providing evidence of the anti-inflammatory effects of fucoidans for advanced cancer patients, and the authors concluded that larger controlled trials are required to establish the efficacy of fucoidan.
Evidence strength: The anti-inflammatory mechanistic evidence is primarily from cell models (in vitro) and is scientifically interesting. The single prospective clinical study was exploratory, uncontrolled, and conducted in a specific patient population (advanced cancer). No robust RCTs in otherwise healthy individuals or with a general anti-inflammatory indication have been conducted using whole bladderwrack.
Since cholesterol is a precursor to sex hormone biosynthesis, kelp consumption may alter circulating sex hormone levels and menstrual cycling patterns. In particular, dietary kelp may be beneficial to women with or at high risk for estrogen-dependent diseases.
The key human study in this area was conducted by Skibola (2004). Intake of bladderwrack was associated with significant increases in menstrual cycle lengths, ranging from an increase of 5.5 to 14 days. Hormone measurements ascertained for one woman revealed significant anti-estrogenic and progestagenic effects following kelp administration. Mean baseline 17β-estradiol levels were reduced from 626 ± 91 to 164 ± 30 pg/ml (P = 0.04) following 700 mg/day, which decreased further to 92.5 ± 3.5 pg/ml (P = 0.03) with the 1.4 g/day dose. Mean baseline progesterone levels rose from 0.58 ± 0.14 to 8.4 ± 2.6 ng/ml with the 700 mg/day dose (P = 0.1), and increased further to 16.8 ± 0.7 ng/ml with the 1.4 g/day dose (P = 0.002).
This was a small study of premenopausal women with abnormal menstrual cycling histories (N=3). The authors noted that these studies would need to be performed in well-controlled clinical trials to confirm these findings.
Evidence strength: Preliminary. This is a case report (n=3), not a controlled clinical trial. The hormonal findings are biologically plausible and the dose-response relationship was suggestive, but no confirmatory trials have been conducted. The findings should be regarded as hypothesis-generating only.
Alginic acid may help lower LDL cholesterol levels according to animal studies, but no human trials have studied this effect of bladderwrack. Brown seaweed extracts containing Fucus vesiculosus have been studied for lipids, blood sugar, and metabolic syndrome; some data suggest modest improvement in HDL cholesterol with a polyphenol-rich extract, while other biomarkers show little or no change. A more recent pilot trial using 5 g daily of dried Fucus in people with type 2 diabetes found no clear differential effect on glucose levels.
Inhibitory activity against angiotensin-converting enzyme I (ACE-I) has been reported for a Fucus spiralis extract; fucoidans are recognized for their cardiovascular and antihypertensive effects through ACE inhibition. Clinical studies evaluating antihypertensive activity of bladderwrack specifically are lacking.
Animal studies using fucoidan isolates at doses of 50–200 mg/kg body weight showed reductions in LDL cholesterol and fasting glucose, but these doses do not translate directly to established human equivalents.
Evidence strength: Weak for human benefit. Animal and in vitro mechanistic data are promising, but clinical trial evidence for cardiometabolic outcomes with bladderwrack specifically is very limited, with available small-scale human data showing inconsistent results.
Bladderwrack's mucilaginous thallus has long been used to soothe irritated and inflamed tissues in the body, and it was historically used as a bulk-forming laxative. Laxative properties have traditionally been attributed to chronic use of bladderwrack and other brown seaweeds and may be due to the component alginic acid, present in many laxative agents.
The sodium salt of alginic acid (sodium alginate, as in Gaviscon®) has been shown to effectively relieve heartburn symptoms compared to other antacids in a double-blind study. Bladderwrack might also help indigestion, though clinical trials have not been conducted.
Evidence strength: For isolated sodium alginate preparations (not whole bladderwrack), there is clinical evidence of antacid efficacy. For whole bladderwrack in digestive conditions, no clinical trials have been conducted; evidence is traditional use only.
A study by Fujimura et al. (2002), published in the Journal of Cosmetic Science, found that treatment of human skin with an extract of Fucus vesiculosus changes its thickness and mechanical properties. Bladderwrack extract applied topically to human skin resulted in a significant increase in skin elasticity.
An extract of F. vesiculosus has been found to stimulate the expression of HO-1 in skin, thereby assisting in the removal of heme catabolites responsible for dark circles under the eye. The extract also demonstrated anti-inflammatory properties which can reduce vasodilation of blood vessels and reduce leakage of heme, and anti-oxidative properties which further improve the appearance of eye bags and wrinkles. The extract also stimulates collagen production, thereby reducing the appearance of fine lines and wrinkles in skin under and around the eye area.
Evidence strength: Preliminary, based on in vitro work and a small number of skin-focused studies. Topical application is considered possibly safe by clinical reviewers. No large-scale controlled human trials on topical bladderwrack for skin outcomes have been identified.
Alginic acid has been shown to inhibit HIV in test tube studies; however, this effect has not been studied in humans. According to test tube and animal studies, fucoidan has antibacterial and anti-HIV activity. Fucoidan is thought to prevent bacteria and viruses from binding to human cells — a necessary step in starting an infection — as opposed to killing the microbes directly, though this has not been definitively proven. To date, no human clinical trials have been done with fucoidan or bladderwrack to support their use for any of these conditions.
Evidence strength: In vitro only. No human clinical evidence for antiviral or antimicrobial clinical benefit.
The sulfated polysaccharides (fucoidans) are well described and considered responsible for many of the observed anticancer effects of F. vesiculosus. Although this is among the most discussed claimed benefits of fucoidan, the existing evidence is clearly insufficient to support its use. Most of the research has been done in cells and only one small clinical trial has been carried out.
An exploratory clinical study showed reduced proinflammatory cytokines (IL-1β, IL-6, TNF-α) in advanced cancer patients receiving fucoidan — the first such study — but larger controlled trials are required to establish efficacy.
Evidence strength: Very preliminary. Evidence is overwhelmingly from in vitro cell lines and animal models. The single human clinical study in advanced cancer patients was exploratory and uncontrolled. Fucoidan should not be substituted for proven anticancer therapies.
Clinical trials are lacking to inform dosing of bladderwrack. Clinical trial data are limited to inform on potential therapeutic applications for F. vesiculosus specifically, with most evidence extrapolated from studies reporting on brown seaweeds generally. Clinical trials of bladderwrack are lacking to inform dosing recommendations.
The following dosages appear in identified sources and are reported only as stated in those sources, not as recommendations:
There is not enough reliable information to know what an appropriate dose of Fucus vesiculosus might be. Bladderwrack's high and variable iodine content (up to 600 mcg per gram) poses a significant risk of thyroid dysfunction, including both hypothyroidism and hyperthyroidism, particularly with chronic use or in individuals with pre-existing thyroid conditions.
Some sources warn against latent hyperthyroidism if Fucus preparations are administered for a long time. It has even been mentioned that iodine in Fucus can cause a thyrotoxic crisis and hypersensitivity reactions. However, it should be noted that the iodine content is variable in seaweeds.
A case report from PubMed documents this risk directly: hyperthyroidism has been attributed to Fucus vesiculosus, which has a high iodine content, in a patient who was also taking lithium. A 60-year-old man taking lithium for bipolar disorder took a herbal extract of Fucus vesiculosus as a laxative. He developed laboratory measures compatible with hyperthyroidism, which resolved after withdrawal of the supplement.
The published conclusion was that Fucus vesiculosus may cause hyperthyroidism given its high iodine content.
People with thyroid disorders should be aware that bladderwrack may contain large amounts of iodine; long-term use or high doses of iodine might make certain thyroid disorders worse. People with autoimmune thyroid disease might be especially sensitive to the harmful effects of iodine.
Bladderwrack might contain heavy metals, which can cause heavy metal poisoning. It is noted as potentially contraindicated in pregnancy and lactation due to iodine excess and potential heavy metal contamination including arsenic, lead, and cadmium. Theoretically there is the potential for toxicity due to heavy metal absorption from brown seaweeds; however, case reports are lacking. Acute toxicity studies in rodents found no evidence of toxic effects following 4 weeks of daily treatment.
Consumption of F. vesiculosus can cause platelet inhibition, which may potentiate the anticoagulant activity of warfarin. Bladderwrack might slow blood clotting, and it might cause extra bleeding during and after surgery. Stopping bladderwrack at least 2 weeks before surgery is advised.
Interactions with amiodarone, ACE inhibitors, medicines dependent on the CYP-450 enzyme system for metabolism, lamotrigine, and vitamin K-influenced anticoagulant agents such as warfarin can theoretically be anticipated; however, case reports are lacking.
Bladderwrack and amiodarone both contain iodine; taking bladderwrack with amiodarone might increase the levels of iodine in the blood, and too much iodine in the blood can cause side effects that affect the thyroid.
Lithium can also change thyroid function. Taking Fucus vesiculosus along with lithium might increase the risk of thyroid function changes.
Bladderwrack can contain significant amounts of iodine, which can affect the thyroid. Taking iodine along with medications for an overactive thyroid might decrease thyroid function too much, or may affect how antithyroid medications work. Some of these medications include methimazole (Tapazole), potassium iodide (Thyro-Block), and others.
Bladderwrack contains iodine, which can increase or decrease thyroid function. Taking Fucus vesiculosus along with thyroid hormone medications might increase the effects of those medications.
Bladderwrack may affect blood sugar levels. For those with diabetes who take medications to lower blood sugar, adding bladderwrack might make blood sugar drop too low.
Fucus vesiculosus is considered possibly unsafe during pregnancy and breast-feeding because it might contain iodine and heavy metals. Excessive consumption of seaweeds during breastfeeding should probably be avoided due to high iodine content and potential contamination with heavy metals.
The severity of adverse event cases was high in six cases reported to the EMA between 2016 and 2021, five of them related to the intake of one homeopathic preparation and the sixth to a food supplement; all products were combination products used for weight control. Six individual cases of low severity were related to the use of a registered product containing Rhamnus frangula, Rhamnus purshianus, and Fucus vesiculosus; adverse events were abdominal pain, diarrhoea, and hypersensitivity, which resolved after discontinuation of treatment.
Minor gastric adverse events have been reported in some seaweed clinical studies, including soft feces and feelings of fullness, possibly due to algin content.
Sustained iodine intakes above regional upper limits increase the chance of thyroid disruption — particularly in people with autoimmune thyroid disease, nodular goiter, or past iodine deficiency. Heavy metal levels depend on water quality and species; reputable suppliers test for inorganic arsenic, cadmium, lead, and mercury and disclose results. Larger, longer trials using single-extract Fucus vesiculosus (not blends) are still limited, and studies often differ in standardization, dosing, timing, and endpoints.
The evidence for Fucus is stronger in chemistry and tradition than in decisive human clinical benefit — that is the most honest summary. Most evidence for bladderwrack is derived from in vitro cell studies and rodent models, with very few randomized controlled trials in humans. Overall, the human clinical evidence base is preliminary and insufficient to support definitive therapeutic claims.
Clinical trial data are limited to inform on potential therapeutic applications for F. vesiculosus specifically, with most evidence extrapolated from studies reporting on brown seaweeds generally. Fucus vesiculosus contains iodine, alginates, fucoidan, phlorotannins, and other marine compounds with plausible effects on satiety, antioxidant activity, metabolic signaling, and thyroid-related physiology. Nevertheless, there is no good scientific evidence to support the use of Fucus vesiculosus for conditions such as thyroid disorders, iodine deficiency, or obesity.
Most of the studies on fucoidan specifically were conducted in animals or isolated cells, and there is a lack of clinical trials to confirm whether fucoidan benefits humans.
Health conditions that Bladderwrack may help support.
Bladderwrack is rich in phlorotannins, fucoxanthin, fucoidan, and vitamins A and C—all demonstrated free-radical scavengers in biochemical and cell assays. Phlorotannins and fucoxanthin quench reactive oxygen species and mitigate UV-related oxidative stress in model systems, with in vitro and limited human cosmetic data.
Alginic acid in bladderwrack forms a gel in the stomach that activates stretch receptors, prolonging satiety. Human studies on alginate supplements have shown reduced hunger and increased fullness after meals. These effects are attributable to the alginate component rather than the whole herb.
Fucoidan from F. vesiculosus shows strong antithrombin and anticoagulant activity in vitro by interacting with heparin cofactor II and antithrombin III. A study published in Oxford Academic confirmed antithrombotic activity in platelet tests. No human anticoagulant clinical trials have been conducted.
Fucoidans exhibit ACE-inhibitory activity in vitro, and the 505-patient Gdue combination product clinical study showed blood pressure reductions. A small 30-person fucoidan human study found lower systolic blood pressure. Direct bladderwrack-specific antihypertensive RCTs are lacking.
Bladderwrack (Fucus vesiculosus) is cited in a PMC peer-reviewed cellulite review (2023) as a supplement used for cellulite via antioxidant effects. A two-phase study showed topical bladderwrack extract increased collagen production 228% in skin samples and significantly reduced cellulite appearance and fat thickness on human upper leg skin over 12 weeks.
Fucoidan and alginic acid in bladderwrack reduce LDL and total cholesterol in animal studies and limited human trials. The 4-month human clinical study reported LDL normalization. The Gdue 505-patient study showed LDL reduction and HDL increase. Animal data are robust; human data are limited.
Fucoidan from Fucus vesiculosus inhibits NF-κB and selectin-mediated cell adhesion and reduces pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in cell models and animal studies. A published PMC in vitro study confirmed anti-inflammatory activity of F. vesiculosus fucoidan across multiple human cell lines. Human RCT data remain limited.
A human pilot case study (Skibola 2004, BMC Complementary Medicine, n=3) found bladderwrack intake significantly reduced serum 17β-estradiol and elevated progesterone in pre-menopausal women with abnormal cycles. Menstrual cycle length increased by 5.5–14 days. Findings are preliminary due to very small sample.
Fucoidan and alginates from bladderwrack resist small-intestinal digestion and reach the colon intact, where they selectively ferment to support beneficial bacteria and short-chain fatty acid production. Preclinical and in vitro human gut model data are available; bladderwrack-specific human trials are limited.
Human clinical trials using a bladderwrack-rockweed combination product (Gdue) demonstrated significant reductions in waist circumference and metabolic syndrome markers over 6 months. Animal studies show fucoidan prevents weight gain on high-fat diets. Thyroid-mediated metabolism support via iodine is the traditional primary mechanism.
Fucoidan in bladderwrack exhibits antithrombotic and anticoagulant activity in platelet models, and the Gdue combination clinical study found reductions in blood pressure, LDL, and triglycerides. Epidemiological data show that regular seaweed consumers have ~12% lower ischemic heart disease risk.
The 2004 Skibola case report (BMC Complement Med, PMID 15294021, n=3) showed bladderwrack intake in pre-menopausal women with abnormal cycles increased cycle length by 5.5–14 days and significantly reduced estradiol while raising progesterone. Evidence is classified scientific due to human data but is very preliminary.
Bladderwrack provides iodine essential for thyroid hormone (T3/T4) synthesis, which governs basal metabolic rate. Iodine-deficiency-related hypothyroidism causes metabolic slowdown; adequate iodine corrects this. This is the best-established mechanism, supported by broad physiological and some clinical evidence.
Topical bladderwrack extract significantly increased collagen production by 228% in human skin samples versus control in a two-phase study. A 12-week topical application trial on human upper leg skin confirmed anti-aging benefit. Fucoidan inhibits collagenase and elastase, enzymes that degrade structural skin proteins.
Fucoidan from F. vesiculosus promotes fibroblast-populated collagen gel contraction through upregulated integrin alpha2beta1 expression, supporting wound contraction and dermal modeling. Human topical studies show improved skin elasticity within 5 weeks. Inhibition of collagenase and elastase also preserves existing matrix.
A human study in patients with elevated triglycerides found bladderwrack supplementation reduced triglyceride levels to normal range within 4 months. Fucoidan metabolic syndrome trials and rodent studies consistently show triglyceride-lowering effects. This is among the better-documented lipid effects.
Bladderwrack contains alginic acid (alginate), the same compound used in the pharmaceutical product Gaviscon to form a protective raft over stomach acid. Traditionally it has been used internally for heartburn and GERD. No clinical trials have tested bladderwrack directly for this indication.
Bladderwrack has been traditionally used both internally and as a topical compress for joint pain and arthritis, attributed to its fucoidan and alginic acid anti-inflammatory content. Animal models show fucoidan reduces joint swelling and inflammatory cytokines. Human clinical trials for arthritis are lacking.
Fucoidan and phlorotannins from bladderwrack inhibit alpha-glucosidase and may lower postprandial glucose in cell and animal models. Fucoidan supplementation in a 30-person human study on metabolic syndrome improved insulin sensitivity, though evidence for bladderwrack specifically as a whole herb in humans remains preliminary.
Bladderwrack's alginic acid is a bulk-forming soluble fiber that absorbs water and adds volume to stool, supporting bowel regularity. It has a documented traditional use as a mild laxative. Clinical trials have not been conducted specifically for this indication.
Bladderwrack's high mucilage and alginic acid content traditionally soothe inflamed gastric mucosa. It is listed in traditional herbal practice for gastritis alongside other mucoprotective herbs. No clinical trials exist for bladderwrack in gastritis specifically.
Bladderwrack (Fucus vesiculosus) is a brown seaweed historically used as a traditional remedy for hypothyroidism due to its high iodine content. It has been recommended since at least the 19th century for goiter and iodine-deficiency hypothyroidism. Its use is appropriate only for iodine-deficiency-driven hypothyroidism, as excess iodine can worsen autoimmune forms.
Bladderwrack has been specifically prescribed in traditional herbal practice for rheumatoid arthritis, used both orally and topically. Fucoidan's ability to modulate immune-inflammatory pathways relevant to RA (NF-κB, cytokine cascades) provides mechanistic plausibility. Human RA clinical trials are absent.
Bladderwrack (Fucus vesiculosus), a brown seaweed, has been used in traditional folk medicine for centuries to treat goiter and thyroid disorders, primarily because of its natural iodine content. It has been used for both hypothyroidism and hyperthyroidism, though modern clinical trial evidence is lacking and effects depend heavily on iodine status.
Bladderwrack (Fucus vesiculosus), a brown seaweed, has been used in traditional European coastal herbal medicine as a mild diuretic and metabolic tonic. Its fucoidan and alginic acid content are attributed with mild diuretic and fluid-regulatory effects. It appears in traditional diuretic formulations and is referenced in legal patent literature as a herbal diuretic agent.
Calcium alginate from bladderwrack has shown promise in animal wound healing models. Fucoidan promotes collagen gel contraction via fibroblast integrin upregulation in in vitro studies. Clinical wound healing evidence for whole bladderwrack in humans is absent; traditional topical use is documented.
Body systems that Bladderwrack may help support.
Go back